At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 14 enrolled
Drug / intervention
Vareniclinedrug
Likely dose
Varenicline 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Varenicline's Clinical Efficacy for Continued Smoking Abstinence When Used in the Clinical Treatment of Schizophrenic Patients Hospitalized in an Institution With a Ban on Cigarette Smoking
Nathan Kline Institute for Psychiatric Research·interventional·Posted Oct 24, 2007·Updated Sep 20, 2018
In Brief
A Phase 4 clinical trial evaluating Varenicline for Schizophrenia and 2 related conditions. Completed, enrolled 14 participants across 1 site.
Detailed Summary
This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and objective measures of smoking, selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline (1-2 mg/day).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Tobacco Use Disorder, Nicotine Dependance
CountriesUnited States
CollaboratorsUniversity of Illinois at Chicago
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedOct 2007
Primary CompletionSep 2009
Study CompletionDec 2010
TodayJul 2026
First PostedOct 24, 2007
Enrollment StartJun 1, 2007
Primary CompletionSep 1, 2009
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.7 years ago
Interventions
Vareniclinedrug
Varenicline 1-2 mg/day